Leadership

Executive Team

Chief Executive Officer

Dr. Raluca Dinu

Chief Financial Officer

Anastas (Stas) Budagov

Chief Operating Officer

Steve Choate

Chief Product Officer

Nasser C. Pirshafiey, MBA

Chief Science Officer

Bilal Malik, Ph.D.

Management Team

Principal Scientist

James Wiskin, Ph.D.

Director, Information Technology

Rob Ruiz

Mr. Steve Choate, appointed as Chief Operations Officer at QT Imaging in March 2024, is responsible for managing the operations organization, ensuring quality, and fostering collaboration with internal, domestic, and international manufacturing partners.

With over 30 years of experience across diverse industries such as aerospace, space, semiconductor, and telecommunications, Mr. Choate has held key leadership positions and brings extensive expertise as a production operations leader with a focus on overseeing manufacturing activities, product development, and production releases.  He served as the VP of Operations at GigOptix, where he oversaw manufacturing on a global scale, Director of Engineering at Teledyne Microwave Solutions, and as an account manager at Endwave, handling various customers in the RF milliwave transceivers space and managing offshore engineering teams.

Mr. Choate began his career at Lockheed Martin, progressing from a design engineer to a role in the program office, where he managed engineering development programs for remote satellite tracking stations. His academic background includes a Bachelor of Science in Mechanical Engineering from San Jose State University and a Master of Science in Mechanical Engineering from Stanford University.

Mr. Greene serves as a director of Umpqua Bank (Nasdaq: UMPQ). He is Founder and Managing Partner of Sky D Ventures, a private equity and advisory services company serving the financial services and FinTech global market. Prior to Sky D Ventures, Mr. Greene was a general partner with an incubator of start-ups focused on digital platforms and solutions from November 2013 to October 2015. He was previously a Vice President with Cisco Systems, Inc. (NASDAQ: CSCO) in its Global Advanced Services Organization, a position he held from February 2012 to September 2013. He joined Cisco in 2005 as Vice President and Global Head of its Financial Services Consulting Business. From there he served as leader of Cisco’s global Strategic Partner Organization. Before Mr. Greene’s tenure at Cisco and Accenture, he generated significant growth as president and CEO of Abilizer, a portal technology start-up company, as managing director at Capgemini, and as global head of financial services at TeleTech. The Company believes that Mr. Greene is qualified to serve on the Board based on his leadership experience with technology companies, as well as his business development and finance experience. Nathan Locke. Mr. Locke joined our Board upon the closing of the Business Combinations in June 2021. Mr. Locke is a Managing Partner and Co-Head of Kayne Anderson Capital Advisors’ growth equity activities. He has spent more than a dozen years at Kayne Anderson identifying and analyzing investment opportunities in technology and 8 TABLE OF CONTENTS tech-enabled service companies, and assisting at the board level in helping those companies as they scale post[1]investment. He has been involved with companies at various stages of growth in healthcare technology and telemedicine, media & telecom, security & compliance and supply chain & logistics. Prior to joining Kayne Anderson in 2008, Mr. Locke worked as a senior analyst on the finance team of Romney for President, Inc., and as the controller for The Commonwealth Political Action Committees. Mr. Locke earned a B.S. in Finance from the University of Utah, where he graduated magna cum laude from the David Eccles School of Business. Following a request by current Class II director Mr. Nathan Locke to not be renominated for election to the Board, the Board has determined not to renominate Mr. Locke. Mr. Locke’s request to not be renominated is not a result of any disagreements with the Company.

Dr. Dinu has spent approximately 25 years in international executive positions within the TMT industry working for privately held start-ups, middle-cap companies, and large enterprises. In these roles, Dr. Dinu has been instrumental in launching and accelerating entities, building teams, large-scale fund raising, developing key alliances and technology partnerships, M&A activities, business development, financial management, global operations and sales and marketing. Dr. Dinu is managing partner of GigCapital Global, a serial issuer of Private-to-Public Equity (PPE) entities, also known as Special Purpose Acquisition Companies (SPACs). Since inception in September of 2017 GigCapital Global (GIG) has issued and completed initial public offerings of six PPE entities, and completed combinations and taking public of five entities; using the PPE platforms; GIG1 combined in November 2019 with Kaleyra (NYSE: KLR), which was sold to Tata Communications in November 2023, GIG2 combined with UpHealth Holding in June 2021 (NYSE: UPH), GIG3 combined in May 2021 with Lightning eMotors (NYSE ZEV), GIG4 combined with BigBear in December 2021 (NYSE: BBAI), and GIG5 combined with QT-Imaging (NASDAQ: QTI) in February 2023.

Dr. Dinu serves as Chair of the Compliance Committee, and member of the Audit Committee and Compensation Committee of UpHealth, Inc. since March 2019, and as a member of the Board of Directors and a member of the Audit Committee of BigBear.ai. Dr. Dinu serves on the board of directors of NY Philharmonic since May 2023.

Dr. Dinu has held leadership positions at several other companies, including at IDT’s Optical Interconnects Division (as vice president and general manager), GigPeak (as executive vice president, chief operation officer, executive vice president of Global Sales and Marketing, and senior vice president of Global Sales and Marketing), Brazil-Photonics (as a director) and Lumera Corporation (as vice president of engineering). Dr. Dinu holds a B.Sc. in Physics and Ph.D. in Solid State Condensed Matter Physics from the University of Bucharest, and an Executive-M.B.A. from Stanford University. Dr. Dinu has an Audit Committee Certificate, Compensation Committee Certificate, as well as a Corporate Director Certificate from Harvard Business School, Executive Education Program.

Ross Taylor has over 30 years of financial experience, both as a chief financial officer and as an equity research analyst on Wall Street. Ross is presently chief financial officer of BillionToOne, a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible.  Previously, he was chief financial officer of Codexis, Inc., an enzyme engineering company.  Prior to Codexis, Ross was chief financial officer of Abaxis Inc., a leading point of care diagnostics company serving the animal health and human health markets, until Zoetis acquired the company for $2 billion.  Ross also served on the board of directors of Scandinavian MicroBiodevices, which was acquired by Zoetis for $80 million.  Prior to Abaxis he had a successful career as an equity research analyst for over 20 years at several Wall Street firms including CL King & Associates, UBS, Smith Barney, and CJ Lawrence.  Ross earned an MBA from Columbia Business School and a Bachelor’s degree in Economics from Duke University.

Zeev Weiner is a professor in obstetrics and gynecology dedicating most of his academic and research career to introduce ultrasound and Doppler ultrasound for women health. From 2014, he is the Chairman of the Division of Obstetrics and Gynecology at Rambam Medical Center and full professor at the faculty of medicine, The Technion Institute of Technology, Haifa, Israel. His sub specialty is Maternal Fetal Medicine and Ultrasound in Obstetrics and Gynecology. His previous clinical position were Director of the Maternal Fetal Medicine Unit at Lutheran Medical Center, Brooklyn, NY, (from 2003 to 2005) and Director of Ultrasound in Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel (from 2005 to 2014).

Professor Zeev Weiner combines clinical activity with research. He has published 200 peer review articles in medical journals, presented many of his research works in international meetings, he has been a reviewer in most prestigious medical journals in obstetrics and gynecology, and an editor in the Life journal. His main field of research has been ultrasound and Doppler ultrasound in Obstetrics and Gynecology. During the nineties, he made a great contribution while introducing color Doppler ultrasound for screening and detecting ovarian cancer, supported by The Israeli Cancer Association. The results of his studies were published in gynecology and ultrasound journals. His studies contributed to the introduction of transvaginal ultrasound and color Doppler ultrasound for the detection of pelvic cancer.

Continuing his research on ultrasound and Doppler ultrasound, Professor Weiner contributed to the detection for fetal anomalies and fetal cardiac circulation. He contributed to the development and the application of the very high-end ultrasound and Doppler ultrasound equipment. For many years, Professor Weiner has been teaching and demonstrating in national and international conferences and seminars the most advanced ultrasound and Doppler ultrasound equipment and modalities. Professor Weiner holds his MD degree from Sackler Faculty of Medicine, Tel Aviv University (1986) and his MHA from Recanati Business school, Tel Aviv University (2012).

Dr. Klock has served as the Chief Executive Officer of QT Imaging since 2014 and as a Director and Founder of QT Imaging since 2011. Prior to serving in these positions with QT Imaging, Dr. Klock was involved in the start-up of five medical companies, including as Co-Founder and President of BioMarin Pharmaceutical, Inc., which successfully commercialized five FDA drugs; and Scientific Founder and Vice President of Research of Glycomed, Inc., which was acquired by Ligand Pharmaceuticals, Inc.

Dr. Klock also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer reviewed medical and scientific publications and has been granted eight patents.

Mr. Dickson has held executive-level positions in companies from Fortune 50 to start-ups and in industries from consumer products to enterprise software. He began his career at General Electric Company, where he held strategic and operating roles on corporate staff and in the company’s $1 billion consumer electronics division. He left GE to join an early-stage company in real-time networked retail distribution, where he was a key player in the company’s IPO. Mr. Dickson then assumed the role of COO for Pine Company, a privately held market research and data management company in Santa Monica, CA, where he repositioned the company as an early player in the customer relationship management (CRM) space. This led to an offer from Draper, Fisher Jurvetson, a Silicon Valley-based venture capital firm, to serve as President and CEO for one of the fund’s portfolio companies.

Mr. Dickson then assumed the position of VP of The Brenner Group, where he led the firm’s interim CEO practice as well as serving as a “parachute CEO” for multiple Silicon Valley-based venture-funded technology companies. These involved firms in the data warehousing, software development, document management, and medical industries, including Armus Corporation, which focused on clinical outcomes for small- and large-scale healthcare providers, and Vital Transport, Inc., which developed an end-to-end system for organ transplant tracking and delivery.

In 2003, Mr. Dickson returned to the East Coast, where he was recruited by Palo Alto Investors to take over as President and CEO of Best Cellars, Inc., an innovative wine retailer with locations from Massachusetts to Texas. During his tenure, the company doubled its sales and created a significant internet business. This led to the company’s acquisition by the $9 billion publicly traded A&P grocery chain in 2007.

More recently, Mr. Dickson has held executive, consulting, and board positions in the wine industry and currently maintains an independent consulting practice focusing on strategic analysis and M&A activities across multiple industries. Mr. Dickson holds a B.S. degree in Marketing and Journalism from Boston University and an M.B.A. degree from Harvard’s Graduate School of Business Administration.

Dr. Katz is a philanthropist, entrepreneur, High-Tech executive, and since 2017 is the Founding Managing Partner and Executive Chairman of GigCapital Global (www.GigCapitalGlobal.com), a serial issuer of Private-to-Public Equity (PPE) entities, also known as Special Purpose Acquisition Companies (SPACs). Since inception in September of 2017 GigCapital Global (GIG) has issued and completed initial public offerings of six PPE entities, and completed combinations and taking public of five entities; using the PPE platforms; GIG1 combined in November 2019 with Kaleyra (NYSE KLR), which was sold to Tata Communications in November 2023, GIG2 combined with UpHealth Holding in June 2021 (NYSE UPH), GIG3 combined in May 2021 with Lightning eMotors (NYSE ZEV), GIG4 combined with BigBear in December 2021 (NYSE BBAI), and GIG5 combined with QT-Imaging (NASDAQ QTI) in February  2023. Dr. Katz is a veteran of more than 35 years of activity with small and middle-size High-Tech companies as founder, chairman of the board of directors, executive and CEO, and as angle and-later stage investor.

Dr. Katz chairs and participates in many boards of directors of private and public High-Tech companies, as well as non-for-profit organizations and, among others, is a member of the board of directors of the New York Philharmonic orchestra. Prior to founding GigCapital Global enterprise in 2017, Dr. Katz bootstrapped GigPeak / GigOptix (NYSE American GIG) in 2007 and led the organization as the chairman of the Board and CEO from the inception and until its sale in 2017 to IDT International (NYSE IDTI).

Prior to funding GigOptix, Dr. Katz has held  CEO and board member positions with privately held companies, including Intransa Inc. and Equator Inc., and earlier he served in several executive positions following his tenure as a member of the technical staff in AT&T Bell Laboratories, Murray Hill, New Jersey in the 80’s and early 90s. Dr. Katz is a graduate of the 1976 class of the Israeli Naval Academy and holds a B.Sc. and Ph.D. in Semiconductors Materials from the Technion (Israel Institute of Technology). Dr. Katz is a serial entrepreneur, holds many U.S. and international patents, has published more than 300 technical papers and is the editor of a number of technical books.

Dr. Dinu has spent approximately 25 years in international executive positions within the TMT industry working for privately held start-ups, middle-cap companies, and large enterprises. In these roles, Dr. Dinu has been instrumental in launching and accelerating entities, building teams, large-scale fund raising, developing key alliances and technology partnerships, M&A activities, business development, financial management, global operations and sales and marketing. Dr. Dinu is managing partner of GigCapital Global, a serial issuer of Private-to-Public Equity (PPE) entities, also known as Special Purpose Acquisition Companies (SPACs). Since inception in September of 2017 GigCapital Global (GIG) has issued and completed initial public offerings of six PPE entities, and completed combinations and taking public of five entities; using the PPE platforms; GIG1 combined in November 2019 with Kaleyra (NYSE: KLR), which was sold to Tata Communications in November 2023, GIG2 combined with UpHealth Holding in June 2021 (NYSE: UPH), GIG3 combined in May 2021 with Lightning eMotors (NYSE ZEV), GIG4 combined with BigBear in December 2021 (NYSE: BBAI), and GIG5 combined with QT-Imaging (NASDAQ: QTI) in February 2023.

Dr. Dinu serves as Chair of the Compliance Committee, and member of the Audit Committee and Compensation Committee of UpHealth, Inc. since March 2019, and as a member of the Board of Directors and a member of the Audit Committee of BigBear.ai. Dr. Dinu serves on the board of directors of NY Philharmonic since May 2023.

Dr. Dinu has held leadership positions at several other companies, including at IDT’s Optical Interconnects Division (as vice president and general manager), GigPeak (as executive vice president, chief operation officer, executive vice president of Global Sales and Marketing, and senior vice president of Global Sales and Marketing), Brazil-Photonics (as a director) and Lumera Corporation (as vice president of engineering). Dr. Dinu holds a B.Sc. in Physics and Ph.D. in Solid State Condensed Matter Physics from the University of Bucharest, and an Executive-M.B.A. from Stanford University. Dr. Dinu has an Audit Committee Certificate, Compensation Committee Certificate, as well as a Corporate Director Certificate from Harvard Business School, Executive Education Program.

Mr. Budagov has served as the Chief Financial Officer of QT Imaging since December 2023. Prior to joining QT Imaging, Mr. Budagov served as an independent consultant at various accounting firms, through which he has been providing consulting services to public and private clients since 2022. Mr. Budagov previously provided financial consulting services to private and public companies while at Acilon Consulting LLC from 2017 until 2022, serving as acting revenue director at Natera, Inc., a public biotech company, acting finance director at Kodiak Sciences, Inc., a public life science company, and a senior manager of more than five IPO projects for clients in the medical device, life science, and biotech industries.

Immediately prior, Mr. Budagov worked at The Siegfried Group, where he was a contractor at Ernst and Young from 2013 to 2016, and advisor to management teams of public companies regarding audit processes, internal controls, and commercial contracts in 2017. Mr. Budagov also has four years of accounting experience, having served as senior accountant at regional public accounting firms. He earned his Bachelor of Science degree in accounting from George Mason University in Fairfax, VA and has been a Certified Public Accountant in the State of Virginia since 2013 and a Certified Internal Auditor since 2017.

Mr. Ruiz has more than 20 years of experience in information technology. Prior to joining QT Imaging, Mr. Ruiz held a variety of positions with increasing responsibility addressing end user computing, global IT infrastructure, data centers, ERP administration, and service management. He has a strong background in ITIL, team development, and process standardization and optimization.

Dr. Wiskin was co-founder of the winner of the 2005 Stoel-Rives Innovation Award for Medical Devices and shared “Utah Best of State” Science and Technology: Medical Innovation, which was then acquired by QT Imaging in 2012.  As Principal Scientist he was involved in the FDA clearance for the first transmission ultrasound tomography of the breast and is actively involved in orthopedic/whole-body cutting-edge research, quantitative breast imaging, and analysis of images.

Dr. Wiskin is an author/co-author on 14 Patents, with several additional patents pending, and he has over 100  peer reviewed papers, book chapters, and presentations, including anchor talks at IEEE and Acoustical Society of America International Symposia.

He has studied the mathematics and physics of wave propagation (EM, acoustic, elastic, quantum) and inverse scattering for over 35 years, and has been elected to the SPIE Medical Imaging Ultrasound Tomography Conference Steering Committee and the IEEE International Ultrasound Symposium Medical Ultrasound Technical Program Committee.

Dr. Wiskin received a Bachelor of Mathematics (Honors, Math & Physics) from the University of Waterloo, Canada, a MSc in Biomathematics from Dalhousie University, Canada, and a Ph.D. in Mathematics from the University of Utah.  He has also received a Descartes Fellowship, University of Waterloo, Graduate Research Fellowship, University of Utah, and was co-author of “Best Paper of the year,” in Computers. and Chemical Eng.

Dr. Bilal Malik has over ten years of experience in research, development, and translation of medical devices, both in academia and industry. He is an expert in leading and directing efforts in image and data science and has a track record of successfully leading innovation for medical imaging products, directing research strategy, and navigating FDA pathways. As Chief Science Officer of QT Imaging, Dr. Malik led the R&D efforts behind the industry’s first-in-class transmission ultrasound breast scanner, from prototyping to FDA clearance and commercialization. As an imaging scientist at Genentech, he provides imaging scientific leadership in late-stage clinical trials in oncology.

Dr. Malik received his BS degree in engineering sciences from GIK Institute, Pakistan, and MS and PhD degrees in electrical and biomedical engineering from Texas A&M University. He has published over 30 peer-reviewed papers and over 60 conference presentations (h-index: 20). He is also a member of the US National Institutes of Health (NIH) medical imaging study section (ISB-10), reviewing grant submissions by small businesses in the area of medical imaging.

For over three decades Mr. Pirshafiey has developed products and businesses for domestic and multinational firms. Mr. Pirshafiey’s creativity, innovative problem-solving skills, and entrepreneurial mindset have provided professional, technical, and business solutions to many start-ups and mature companies.

In 2014, Mr. Pirshafiey joined the QT Imaging startup company, where he led the technology group in production design and commercialization of the novel breast imaging modality, while further developing the technology for other imaging applications, including diagnostic imaging of human extremities, joints, infant imaging, and imaging internal organs. He led the technology team members—building a focused team of mechanical, electrical, software, science, and image reconstruction scientists. Additionally, Mr. Pirshafiey established the breast imaging device manufacturing team.

Mr. Pirshafiey has previously founded and managed two companies with the mission to provide sustainable practices to industries such as medical devices, automotive, aerospace, high-tech, consumer products, and robotics (brief client list: Johnson & Johnson, Siemens, Edwards Life Sciences, Autoliv, TRW).  Mr. Pirshafiey has 18 inventions filed with the US patent office, holds a Bachelor of Science in Aeronautical Engineering, and an MBA with specialization in Entrepreneurship.

On a personal note, Mr. Pirshafiey is a Multiengine Instrument Rated Commercial pilot, who enjoys sharing his passion of flying by being part of the Angle Flight West team. A group of volunteers and pilots, who provide free medical transportation to people in need.

Skip to content